Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 1341Glioblastoma 493Gliosarcoma 470Osteosarcoma 364Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 252Neoplasms 231Glioma 230Lymphoma 227Rhabdomyosarcoma 209Neuroblastoma 209Breast Neoplasms 205Sarcoma, Ewing 203Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 183Ovarian Neoplasms 177Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 169Lymphoma, Follicular 158Liposarcoma 144Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dendritic Cell Sarcoma, Follicular × Sarcoma × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡